Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
Ironwood spies new frontier for $1B drug in exploratory trial
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
Ironwood`s bowel disease drug meets main goal of late-stage study
Ironwood Announces Positive Results from Phase III of Once-Weekly Apraglutide